Polymyxin B (PMB) is often considered as the last line of defense for treating carbapenem‐
resistant Klebsiella pneumoniae (CRKP). However, its efficacy is hindered by limited …

The epidemic of multidrug-resistant Gram-negative bacteria is an ever-growing global
concern. Polymyxin B (PMB), a kind of “old fashioned” antibiotic, has been revived in clinical …

Polymyxins are the last line of defense against multidrug-resistant (MDR) Gram-negative
bacterial infections. However, this last resort has been threatened by the emergence of …

The pandemic of multidrug-resistant Gram negative bacteria (GNB) is a worldwide
healthcare concern, and very few antibiotics are being explored to match the clinical …

The escalating issue of lung infections induced by multi‐drug resistant (MDR) bacteria is
threatening human health. Thus, the development of efficient drug delivery systems is …

Bacterial infection causes lung inflammation and recruitment of several inflammatory factors
that may result in acute lung injury (ALI). During bacterial infection, reactive oxygen species …

Modern medicine continues to struggle against antibiotic-resistant bacterial pathogens.
Among the pathogens of critical concerns are the multidrug-resistant (MDR) Pseudomonas …

Nucleic acid-based materials showcase an increasing potential for antimicrobial drug
delivery. Although numerous reports on drug-loaded DNA nanoparticles outline their pivotal …

Chronic lung infection caused by bacterial biofilms is an extremely serious clinical problem,
which can lead to the failure of antibiotic therapy. Although nanoparticles have shown great …

Mycobacterium tuberculosis (Mtb), causative agent of tuberculosis (TB) and non-tubercular
mycobacterial (NTM) pathogens such as Mycobacterium abscessus are one of the most …